Pfizer Inc. has announced positive topline results from its phase 3 TALAPRO-3 study, highlighting the impact of Talzenna Xtandi trial outcomes in advanced prostate cancer.
Pfizer Inc. today reported positive topline findings from its Phase 2 FOURLIGHT-1 trial, marking a key milestone in the atirmociclib breast cancer study for patients with HR-positive HER2-negative metastatic breast cancer...
Sun Pharma moves closer to expanding Ilumya’s use as the US FDA begins reviewing its application for psoriatic arthritis, backed by late-stage trial data showing promising results.
.png)
Caplin Steriles has received USFDA approval for its Sodium Phosphates Injection USP in multiple strengths, allowing the company to expand its injectable drug portfolio and strengthen its presence in the U.S. hospital and critical care market.
Deloitte India launches ConnectSafe, a first-of-its-kind cybersecurity facility enabling real-world cyber threat simulation to strengthen protection for connected systems and critical infrastructure.
Zydus Lifesciences has launched Diasens and GlucoLive, its new AI-powered continuous glucose monitoring devices. The system streams real-time glucose data to smartphones and connects patients, caregivers, and doctors through the GoodFlip digital care
.jpeg)
India’s rare disease ecosystem took centre stage at the Rare Diseases Action Summit 2026 in New Delhi, organised by the IHW Council, bringing together policymakers, healthcare leaders, patient advocates, industry experts and researchers to discuss so
Aurobindo Pharma said its Unit IV facility operated by APL Healthcare has received a Voluntary Action Indicated (VAI) classification from the U.S. Food and Drug Administration following a recent inspection, indicating minor observations with no regul
Mankind Pharma and health experts emphasize early screening for chronic kidney disease (CKD) on World Kidney Day, urging proactive kidney health and regular check-ups to prevent progression.
Pfizer reported positive results for its experimental eczema drug tilrekimig after it met the main goal in a Phase 2 trial for moderate-to-severe atopic dermatitis. The company now plans to move the treatment into late-stage Phase 3 testing.
.jpg)
.jpg)
, CDSCO.jpg)